



Reduction of sick leave by a workplace educational low back pain intervention: A cluster randomized controlled trial

Journal:	<i>Scandinavian Journal of Public Health</i>
Manuscript ID	SPUB-RI-2016-0116.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	07-May-2016
Complete List of Authors:	Ree, Eline; Uni Research, Uni Research Health Lie, Stein Atle; Universitetet i Bergen Det medisinsk-odontologiske fakultet, Department of Clinical Dentistry Eriksen, Hege; Uni Research AS, Uni Research Health; Hogskolen i Bergen, Department of Sport and Physical Activity Malterud, Kirsti; Uni Research AS, Uni Research Health; Universitetet i Bergen Det medisinsk-odontologiske fakultet, Department of Global Public Health and Primary Care Indahl, Aage; Vestfold Hospital Trust, Division of Physical Medicine and Rehabilitation Samdal, Oddrun; Universitetet i Bergen Det Psykologiske Fakultet, Department of Health Promotion and Development Harris, Anette; Universitetet i Bergen Det Psykologiske Fakultet, Department of Health Promotion and Development; Universitetet i Bergen Det Psykologiske Fakultet, Department of Psychosocial Science
Problem Areas and Research:	Sickness leave, Musculoskeletal diseases
Discipline:	Prevention and Health Promotion
Methodology:	Community Intervention

SCHOLARONE™
Manuscripts

1
2
3 **Reduction of sick leave by a workplace educational low back pain intervention: A**
4 **cluster randomized controlled trial**
5
6
7
8

9 Eline Ree ^{1,2}, Stein Atle Lie ³, Hege R Eriksen ^{1,4}, Kirsti Malterud ^{1,5,6}, Aage Indahl ²,
10 Oddrun Samdal ⁷, Anette Harris ^{7,8}
11
12

13 ¹Uni Research Health,
14 Uni Research,
15 Bergen, Norway
16
17

18 ²Division of Physical Medicine and Rehabilitation,
19 Vestfold Hospital Trust,
20 Stavern, Norway
21

22 ³Department of Clinical Dentistry,
23 Faculty of Medicine and Dentistry, University of Bergen,
24 Bergen, Norway
25

26 ⁴Department of Sport and Physical Activity,
27 Bergen University College,
28 Bergen, Norway
29

30 ⁵Department of Global Public Health and Primary Care,
31 University of Bergen,
32 Bergen, Norway
33

34 ⁶The Research Unit for General Practice and Section of General Practice,
35 Department of Public Health, University of Copenhagen,
36 Copenhagen, Denmark
37

38 ⁷Department of Health Promotion and Development,
39 Faculty of Psychology, University of Bergen,
40 Bergen, Norway
41

42 ⁸Department of Psychosocial Science
43 Faculty of Psychology, University of Bergen
44 Bergen, Norway
45
46
47
48
49

50
51 Corresponding author:

52 Eline Ree, Uni Research Health, Nygårdsgaten 112-114, 5008 Bergen, Norway
53 Phone: + 47 90 04 27 92 - Email: eline.ree@uni.no
54

55
56 Number of words (abstract, ref list, headings, tables, and figures not included): **3526**
57
58
59
60

Abstract

Aims: To investigate whether a workplace educational back pain intervention has an effect on sick leave at individual level and to identify possible predictors of the intervention effect.

Methods: Work-units in two municipalities were cluster-randomized to (1) educational meetings and peer support (45 units), (2) educational meetings, peer support, and access to an outpatient clinic if needed (48 units) or (3) control (42 units). Both intervention groups had educational meetings with information about back pain based on a “non-injury model”. A “peer advisor” was selected among their colleagues. Outcome was days of sick leave at individual level at 3, 6, 9 and 12 months, adjusting for previous sick leave at unit level. Due to similar effect on sick leave the two intervention groups were merged ($n=646$) and compared to controls ($n=211$). Predictors were different levels of belief in back pain myths, pain-related fear, helplessness/hopelessness, and low back pain.

Results: The intervention group had significantly less days of sick leave at 3 months (4.9 days, $p=.001$) and at 6 months (4.4 days, $p=.016$) follow-up, compared to the control group. At three months, a low level of pain-related fear was the only predictor for intervention effect (8.0 less days of sick leave, $p<.001$).

Conclusions: A workplace educational back pain intervention had an effect on sick leave up to six months. Low score on pain-related fear was a predictor of the intervention effect.

Trial registration ClinicalTrials.gov, registration number: NCT00741650

Key words: work intervention; health education; health communication; psychological adaption; helplessness; hopelessness; low back pain; sick leave

Introduction

Neck and low back pain (LBP) are the most common complaints related to long-term sick leave and disability in Norway [1], and LBP is globally related to more disability than any other condition [2]. Despite great research effort, the evidence regarding prevention of LBP is scarce [3]. It seems difficult to prevent low back pain, but research has shown that it is possible to prevent the consequences of low back pain, such as sick leave, fear of movement or injury and inactivity [3]. Therefore, it is important to prevent these negative consequences of LBP [3].

Brief interventions based on a “*Non-Injury Model*” (NIM) with the aim to prevent consequences of LBP have shown success in increasing return to work (RTW) in clinical populations [4-6], and in reducing sick leave among employees [7, 8]. NIM is proposed by Indahl [4], and is in line with the European guidelines for the prevention of LBP [3].

According to NIM, the spine is considered to be a strong structure and pain is seldom a sign of an injury or disease caused by strain, but rather a functional disturbance [4]. Interventions based on NIM are effective regarding RTW among LBP patients for a substantial proportion of the participants [3-6]. More information concerning possible predictors for effect of such interventions in preventing sick leave will provide valuable knowledge for future interventions.

For those who are already on sick leave due to LBP, fear avoidance beliefs, low internal health locus of control, and negative expectancy of recovery are negative predictors for RTW [6, 9, 10]. Fear avoidance beliefs are associated with sick leave, even when controlling for LBP, previous sick leave, age and work environmental factors [11]. However, evidence from non-clinical populations is scarce, and it is therefore of interest to explore if beliefs and expectancies are valid as predictors of remaining at work in a non-patient population.

1
2
3 In the current study, we have explored this issue in a sample of Norwegian employees who
4 participated in atWork, a cluster randomized controlled trial of a workplace intervention
5 based on NIM. The aim with atWork was to prevent and manage negative consequences of
6 LBP in a population of municipal employees, and it proved to be effective in reducing sick
7 leave at group level at one year-follow up [8]. The current study contributes with longitudinal
8 individual-level data on sick leave among employees who participated in atWork, consenting
9 to gather individual data.
10
11

12
13
14 Changing misconceptions about low back pain and enable the employees to cope with back
15 and neck pain at the workplace, is the core of atWork. The Cognitive Activation Theory of
16 Stress (CATS) [12] is therefore an important theoretical framework for the intervention.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CATS defines coping, which is essential for health, as the acquired expectancy that most or all responses lead to a positive result. Hopelessness (negative response outcome expectancy) and helplessness (no response outcome expectancy) on the other hand, are associated with sustained activation, which may have major implications for health [12].

The aim of the current study was to investigate the effect of atWork on sick leave at individual level, and to investigate whether belief in back pain myths, pain-related fear, helplessness/hopelessness, and LBP predict the effect of the atWork intervention.

Materials and Methods

Participants and procedure

In the period 2008-2010, all employees in two Norwegian municipalities were invited to participate in the atWork intervention. It was estimated to be around 3500 employees in total in the two municipalities at the initiation of the study. The effect of the intervention on sick leave at unit level and details of procedure and interventions are published elsewhere [8].

Since the intervention was carried out in workplace units, a cluster-randomized design was

1
2
3 chosen. 125 work units (clusters) in the municipalities were randomized into three groups: (1)
4
5 educational meetings and peer support, (2) educational meetings, peer support and access to
6
7 an outpatient clinic, or (3) control group that received treatment as usual (Figure 1).
8

9
10 Randomization of whole units, stratified according to sectors (i.e., schools, nursing homes
11
12 etc.) was done at Uni Health using computer generated, random numbers. Due to the nature
13
14 of the intervention, it was not possible to blind participants of their allocation.
15

16
17 All employees who were randomized to any of the intervention groups received 2-4
18
19 educational meetings at the workplace. At these meetings evidence-based information about
20
21 LBP based on NIM and the European guidelines for LBP was presented [6, 7]. At each work
22
23 unit, a peer advisor was selected among the employees. The peer advisor was a colleague
24
25 who received a brief education regarding back pain, and should assist colleagues with
26
27 information and support to increase their likelihood to stay at work. Additionally, in the
28
29 intervention group with access to an outpatient clinic, the peer advisor could, if needed,
30
31 directly refer the employee to the clinic.
32
33

34
35 The control group did not receive any intervention. Both the control group and the
36
37 intervention groups were free to receive treatment as usual from GPs and the remaining
38
39 Norwegian health care system.
40

41
42 At baseline, 1746 employees responded to the questionnaire, giving a response rate of
43
44 approximately 50%. Together with the baseline questionnaire, the participants received a
45
46 consent form where we asked them for permission to collect register data on sick leave from
47
48 NAV. Only data from employees providing such consent are included in this study ($n=795$).
49
50 Furthermore, participants with missing data on workplace unit ($n=94$) were excluded, as this
51
52 information was necessary to know which group the participants were randomized to. The
53
54 two intervention groups were combined into a single intervention group, because few
55
56 workers went to the outpatient clinic, and the result from either intervention was similar on
57
58
59
60

1
2
3 sick leave. Consequently, 646 (mean age = 44.2 years (SD = 10.81), 86% females)
4
5 constituted the intervention group, and 211 (mean age = 43.1 years (SD = 11.62), 88.2%
6
7 females) the control group (Figure 1).
8
9

10 INSERT FIGURE 1 HERE
11

12 13 *Ethics*

14
15
16 The study followed the Helsinki declaration, and was approved by the Norwegian Regional
17
18 Ethics Committee in Western Norway (REK vest, ID 6.2008.117). The Norwegian Social
19
20 Science Data Services recommended the study (NSD, ID 18997), as well as the privacy
21
22 authority at the Oslo University Hospital (Rikshospitalet, ID 08/2421).
23
24

25 26 *Instruments*

27
28
29 **Outcome variable.** Sick leave was measured at individual level by individual registry data
30
31 from the Norwegian Labour and Welfare Administration (NAV). In Norway the employer
32
33 pays the first 16 calendar days of a sick leave period. After the 16 days period, NAV covers
34
35 the disbursement with sick leave benefits equal to 100% of past earning. The available data
36
37 were based on the sickness payment database from NAV. In cases where the employees were
38
39 sick listed for more than 16 days, these 16 days were also included in the data material. In the
40
41 present study the number of days on sick leave was calculated for the 12 months both prior to
42
43 and after the intervention.
44
45

46
47
48 **Predictor variables.** All predictor variables were measured at baseline.
49

50
51 *Low Back Pain (LBP)* was measured by a single item from the Subjective Health Complaints
52
53 (SHC) inventory [13], asking if the participants had experienced LBP in the last 30 days. The
54
55 item was rated on a four-point scale from 0 = “no complaints” to 3 = “serious complaints”.
56
57 The item was dichotomized to 0 (no or some complaints) and 1 (much or severe complaints).
58
59
60

1
2
3 *Attitudes and beliefs regarding LBP* were measured by two items from Deyo's "back pain
4 myths" [14]. Originally, Deyo [14, 15] proposed seven myths that represent misconceptions
5 regarding LBP. Two of these myths were explored in the current study, as these are
6 specifically addressed in atWork [8], in addition to being the most prevalent in the general
7 population [15]: 1) "Most back pain is caused by injury and heavy lifting" (Myth lifting) and
8 2) "Everyone with back pain should have a spine X-ray" (Myth X-ray). The items were rated
9 on a five-point scale from 1 = "totally disagree" to 5 = "totally agree". The items were
10 dichotomized to 0 = "totally disagree", "disagree", "neither disagree nor agree", and 1 =
11 "agree" and "totally agree".
12
13
14
15
16
17
18
19
20
21
22
23

24 *Pain related fear* was measured by the Tampa Scale for Kinesiophobia (TSK). The scale
25 consists of 13 items measuring fear of back (re)injury due to movement [16, 17], rated on a
26 four-point scale from 1 = "totally disagree" to 4 = "totally agree". The scale was
27 dichotomized based on the mean value for the sum-score (mean = 25.4) into 0 = low (below
28 the mean) and 1 = high (above the mean).
29
30
31
32
33
34

35 *Helplessness and Hopelessness* were measured by six items from the Theoretically
36 Originated Measure of the Cognitive Activation Theory of Stress (TomCats) [18], designed
37 to measure response outcome expectancies in CATS [12]. The scale consists of three factors,
38 representing the three response outcome expectancies in CATS. In the current study,
39 helplessness and hopelessness were treated as one single factor based on factor analysis from
40 a previous publication from the same sample [19]. Examples of statements are: "I really don't
41 have any control over the most important issues in my life" (helplessness), and "all my
42 attempts at making things better just make them worse" (hopelessness). All items were rated
43 on a five-point scale from 1 = "not true at all" to 5 = "completely true". The scale was
44 dichotomized based on the mean value (mean = 10.2) into 0 = low (below the mean) and 1 =
45 high (above the mean).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analyses

Differences between the intervention and the control group at baseline on the predictor variables were tested with independent-samples t-tests.

Means, standard deviations, and percent of participants on sick leave in three-month periods one year before and the year after the intervention were calculated. Means and 95% confidence intervals were calculated for sick leave days stratified by the predictors (high/low) in the intervention and control group the year after the intervention.

Sick leave days in three-month periods the year after the intervention were analyzed using generalized estimating equations (GEE) [20]. Using this approach, corrections for the clustered nature of the data were accounted for [21]. The analyses were based on least squares estimators and identity link function. Standard errors were calculated based on a robust variance estimator, corrected for clustering of data. Differences in days of sick leave the year preceding the intervention were adjusted for in the analyses to control for differences in initial sick leave between the intervention and control group. No further variables were adjusted for in the analyses. Adjustment for clustering was done at unit level, i.e. on workplace department.

For differences in effect on days of sick leave between intervention and control group, adjusted mean difference scores and 95% confidence intervals with corresponding *p*-values were calculated. Six models including the interaction effect of days of sick leave for the dichotomized (high/low) predictors and intervention were conducted to test if there were statistically significant differences between the intervention and control group regarding the effect of the predictors on sick leave. There was one for the total effect, and five for each of the predictors. Selection of the predictors was based on the theoretical framework of the atWork intervention, i.e. the non-injury model and CATS. The interaction terms were

1
2
3 composed by dummy variables for the predictors and dummy variables for the time
4
5 dimension. Each model included four interactions terms based on the four time periods; 0-3,
6
7 3-6, 6-9, and 9-12 months.
8
9

10 For significant results, stratified analyses of the predictors were conducted to calculate the
11
12 effect within the two categories (high/low).
13

14
15 The statistical analyses were performed using SPSS® version 21.0 (IBM Corporation,
16
17 Armonk NY, USA) for Windows. *p*-values lower than 5 % (0.05) were considered
18
19 statistically significant.
20
21

22 23 **Results**

24 25 *Descriptive statistics*

26
27
28
29 There were no statistical significant differences at baseline between the intervention and
30
31 control group in the predictor variables (Table1).
32
33

34
35 The prevalence of days of sick leave the year before the intervention differed between the
36
37 intervention and the control group (Table 2). Mean scores for overall sick leave days,
38
39 stratified by high and low baseline scores on the predictor variables in the intervention and
40
41 control group are presented in Table 3.
42
43

44
45 INSERT TABLE 1 HERE
46

47
48 INSERT TABLE 2 HERE
49

50
51 INSERT TABLE 3 HERE
52

53 54 *The effect of the atWork intervention on sick leave*

55
56 The adjusted analyses showed a statistically significant effect of the intervention on days of
57
58 sick leave the first six months subsequent to the intervention (Table 4). Employees in the
59
60

1
2
3 intervention group had on average an effect of 4.9 less days of sick leave the first three
4 months and 4.4 less days of sick leave the next three months after participating in the
5 intervention, compared to the control group (See Table 2 for means and SD; Table 4). When
6 calculating the difference between the groups based on estimated and adjusted means, the
7 difference in change was 45.6% the first three months, and 41.4% the next three months.
8 There was no statistically significant effect of the intervention on days of sick leave
9 subsequent to the first six months (Table 4).
10
11
12
13
14
15
16
17
18

19 *The effect of the intervention on sick leave within different levels of beliefs, expectancies and*
20 *low back pain*
21
22
23

24 There was a statistically significant effect of the intervention on days of sick leave for the
25 different levels of pain-related fear measured at baseline the first three months (Table 4).
26 Thus, stratified analyses of this predictor were conducted to calculate the effect within the
27 two categories (high/low). The adjusted mean difference between the intervention and control
28 group on low pain-related fear the three first months was -8.03 (95% CI: -12.88 – -3.17, $p <$
29 .001), indicating that employees in the intervention group with low (≤ 25.4) scores had on
30 average an effect of 8.03 less days of sick leave the first three months after participating in
31 the intervention, compared to the control group (See Table 3 for means and 95% CI). When
32 calculating the difference between the intervention and control group within the low levels of
33 pain-related fear, the difference in change was 67.8% the first three months. There was no
34 statistically significant effect of the intervention for the levels of pain-related fear subsequent
35 to the first three months.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 There were no statistically significant differences in effect of the intervention between
52 individuals with high and low scores on the other predictor variables (back pain myths,
53 helplessness/hopelessness and low back pain) (Table 4). Thus, stratified analyses of these
54 predictors to calculate the effect within the two categories were not conducted.
55
56
57
58
59
60

1
2
3 INSERT TABLE 4 HERE
4
5

6 **Discussion**
7

8
9 The main aim of this study was to investigate if there was an effect of atWork on sick leave,
10 and to identify baseline characteristics with the participants that could contribute to this
11 effect. There was an effect on sick leave the first six months subsequent to the intervention.
12
13

14
15 This is in line with, but expands on the findings by Odeen et al. [8] by showing individual
16 effects among those consenting to gather individual data and also showing exactly when
17 during the first year the effect occurred. Our result regarding the short-term effect is also in
18 accordance with a previous similar intervention study among LBP patients [5]. However,
19 effects on RTW are found for up to five years in a clinical population [6]. In a clinical setting
20 the message is tailored to fit the individual need, which might result in a stronger effect than
21 in the atWork study designed to reach all employees present at work. Still, the effect of
22 atWork on sick leave is important, since population-based preventive interventions often
23 requires long-term implementation for an effect to occur [22].
24
25
26
27
28
29
30
31
32
33
34
35
36

37 In the current study, low scores on pain-related fear predicted effect of the intervention. The
38 result is in accordance with a recent systematic review of back pain interventions showing
39 that high fear-avoidance beliefs at baseline were associated with poor treatment outcomes in
40 terms of more pain and/or disability and less RTW [10]. Also in line with the present study,
41 Staal et al. [23] found that workers with scores equal to or above the median on fear
42 avoidance beliefs at baseline return to work more slowly after participating in a graded
43 activity intervention than those with scores below the median.
44
45
46
47
48
49
50
51
52

53 While expectancies are generalized, pain-related fear represents specific beliefs regarding
54 fear of movement or (re)injury when in pain, which might explain why pain-related fear was
55 the only significant predictor in this study. In a previous qualitative study, participants in an
56
57
58
59
60

1
2
3 educational intervention similar to atWork, emphasized trust in the professionals and
4 improved understanding as important aspects contributing to their coping with the complaints
5 [24]. Strong pain-related fear can hamper confidence in the professionals and the information
6 they receive from the intervention. Furthermore, the non-injury model might be more
7 conceivable for employees with low pain-related fear. For employees with low or moderate
8 scores on pain-related fear, atWork might provide the reassurance they need to be able to stay
9 at work despite pain. Employees with strong and deep-rooted pain-related fear may need
10 something else, e.g. more extensive, multidisciplinary treatments than what was provided in
11 atWork, or an intervention targeting pain related fears, including performance of practical
12 tasks. Cognitive behavior therapy (CBT) has shown to be effective in reducing avoidance,
13 catastrophizing, and disabling beliefs among LBP patients [25], but might also have a
14 negative effect on disability for individuals with low scores on fear avoidance [26].
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 *Strengths and limitations*

31
32
33 A major strength of the current study is that the outcome is measured by registry data on sick
34 leave that are considered highly accurate and thus reduce the risk of measurement errors. The
35 sample is relatively large, and due to the sample diversity regarding workplace size and work
36 tasks, the possibility of group specific effects and localization effects are reduced. The high
37 predominance of women in the sample (87.2%) is representative for the municipality sector
38 in Norway [27]. A further strength of the study is that all unit types (e.g. kindergartens,
39 nursing homes etc.) were represented in the sample, and there was no systematic dropout
40 from any unit types on responses to the questionnaire.
41
42
43
44
45
46
47
48
49
50

51
52 The current study contributes to increase knowledge concerning the effect of a work place
53 based low-cost and low-threshold sick leave intervention. Municipal employees have
54 relatively high sickness absence compared with employees in private and state-level public
55
56
57
58
59
60

1
2
3 sector [28]. This study addresses one of the sectors with the highest rates of long-term sick
4
5 leave.
6
7

8 A limitation of this study is the lack of a published protocol. The low response rate of
9
10 approximately 50% might increase the risk of non-response bias and limit the validity of the
11
12 findings. It would have been relevant to investigate whether men and women have different
13
14 effect of the intervention, but the low number of men in the study could not justify such
15
16 analyses. Caution should be made when generalizing to private sector employees and to men.
17
18

19
20 In cases where the employee is sick listed for 16 days or less, the sick leave is not registered
21
22 in NAV, and thereby missed in this study. Although we were most interested in the long-term
23
24 sick leave due to its negative consequences both for the individual and the society, it would
25
26 have been interesting to also see how the intervention affected the short-term sick leave. Due
27
28 to data protection issues, information about which diagnoses the individuals were sick listed
29
30 for was not available. However, there is a high degree of comorbidity in subjective health
31
32 complaints [29], and huge variation regarding which diagnosis the general practitioner choose
33
34 when presented for the same patient [30], making the specific diagnoses less relevant in this
35
36 setting.
37
38

39
40 A further limitation of the current study is that we cannot exclude the possibility of
41
42 confounding variables as the unit of randomization was different from the unit of analysis.
43
44 However, adjustment for sick leave the year before the intervention and for clustering of the
45
46 data within the unit of randomization justifies the analyses. Some of the sub groups were
47
48 small. This results in wide confidence intervals, which also indicates low power for these
49
50 analyses.
51
52

53
54
55 *Implications*
56
57
58
59
60

1
2
3 Knowledge on individuals who benefit from work place interventions is important for
4
5 authorities regarding whom to focus in such interventions. Still, excluding workers with high
6
7 levels of pain-related fear seems unrealistic as well as unethical. The intervention has a
8
9 preventive approach towards all employees present at work. More knowledge of
10
11 characteristics about individuals with high scores on pain-related fear, and why they do not
12
13 respond to interventions such as atWork is needed. Furthermore, future studies should
14
15 explore mediational effects, i.e. whether expectancies and beliefs change as a result of the
16
17 intervention, and if these changes predict effect on sick leave.
18
19

20 21 **Conclusions**

22
23
24 The atWork intervention had an effect on days of sick leave at individual level the first six
25
26 months subsequent to the intervention, and low levels of pain related fear predicted the effect.
27
28 There were no differences in effect of the intervention between individuals with high and low
29
30 scores on helplessness and hopelessness, belief in the back pain myths and low back pain.
31
32 Since the effect of atWork on sick leave was limited to the first six months, indicating a need
33
34 for repetition of the intervention message, the educational part of atWork should be tested in
35
36 primary health care, and considered implemented as a part of regular practice in primary care
37
38 if the results are positive.
39
40
41
42

43 **Acknowledgements**

44
45
46 The study was financially supported by the Norwegian Extra Foundation for Health, by the
47
48 South-Eastern Norway Regional Health Authority and by the Hospital at Vestfold, Stavern.
49
50 Thanks to Erik Lindh and Magnus Odeen for coordinating the project, and to Camilla
51
52 Ihlebæk for assisting in the design and in conducting the study. Thanks to Britt Øvregård and
53
54 Berit Borge at the municipalities for help in the project and to Nina Konglevoll for technical
55
56 assistance.
57
58
59
60

Conflicts of interest

The authors declare that there is no conflict of interest.

References

1. NAV [Norwegian Labour and Welfare Administration]. Legemeldte sykefraværsdagsverk 4 kv 2005-2014 Diagnose og kjønn, <https://www.nav.no/no/NAV+og+samfunn/Statistikk/Sykefravar+-+statistikk/Tabeller/legemeldte-sykefrav%C3%A6rsdagsverk-4-kv-2005-2014-diagnose-og-kj%C3%B8nn> (2015, accessed 10 September 2015)
2. Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014; doi: 10.1136/annrheumdis-2013-204428.
3. Burton AK, Balague F, Cardon G, Eriksen HR, Henrotin Y, Lahad A et al. Chapter 2 - European guidelines for prevention in low back pain. *Eur Spine J* 2006;15: 136.
4. Indahl A, Velund L, Reikeraas O. Good Prognosis for Low Back Pain When Left Untampered: A Randomized Clinical Trial. *Spine (Phila Pa 1976)* 1995;20 4: 473-7.
5. Hagen EM, Grasdahl A, Eriksen HR. Does Early Intervention With a Light Mobilization Program Reduce Long-Term Sick Leave for Low Back Pain: A 3-Year Follow-up Study. *Spine (Phila Pa 1076)* 2003;28 20: 2309-15.
6. Indahl A, Haldorsen EH, Holm S, Reikeras O, Ursin H. Five-year follow-up study of a controlled clinical trial using light mobilization and an informative approach to low back pain. *Spine (Phila Pa 1976)* 1998;23 23: 2625-30.
7. Werner EL, Lærum E, Wormgoor MEA, Lindh E, Indahl A. Peer support in an occupational setting preventing LBP-related sick leave. *Occup Med (Lond)* 2007;57 8: 590-5.
8. Odeen M, Ihlebæk C, Indahl A, Wormgoor MA, Lie S, Eriksen H. Effect of Peer-Based Low Back Pain Information and Reassurance at the Workplace on Sick Leave: A Cluster Randomized Trial. *J Occupational Rehabil* 2013;23 2: 209-19.
9. Reme SE, Hagen EM, Eriksen HR. Expectations, perceptions, and physiotherapy predict prolonged sick leave in subacute low back pain. *BMC Musculoskelet Disord* 2009;10 1: 139-47.
10. Wertli MM, Rasmussen-Barr E, Held U, Weiser S, Bachmann LM, Brunner F. Fear-avoidance beliefs—a moderator of treatment efficacy in patients with low back pain: a systematic review. *Spine J* 2014;14 11: 2658-78.
11. Jensen JN, Karpatschhof B, Labriola M, Albertsen K. Do Fear-Avoidance Beliefs Play a Role on the Association Between Low Back Pain and Sickness Absence? A Prospective Cohort Study Among Female Health Care Workers. *J Occup Environ Med* 2010;52 1: 85-90.
12. Ursin H, Eriksen HR. The cognitive activation theory of stress. *Psychoneuroendocrinology* 2004;29: 567-92.
13. Eriksen HR, Ihlebæk C, Ursin H. A scoring system for subjective health complaints (SHC) *Scand J Public Health* 1999;1: 63-72.
14. Deyo RA. Low-back pain. *Sci Am* 1998;279 2: 48-53.
15. Ihlebæk C and Eriksen HR. Are the "myths" of low back pain alive in the general Norwegian population?. *Scand J Public Health* 2003;31: 395-8.

- 1
2
3 16. Kori SH, Miller RP, Todd DD. Kinesiophobia: a new view of chronic pain behavior. *Pain Man* 1990; 35-43.
- 4
5 17. Haugen AJ, Grøvle L, Keller, Grotle M. Cross-Cultural Adaptation and Validation of
6 the Norwegian Version of the Tampa Scale for Kinesiophobia. *Spine* 2008;33 17:
7 595-601.
- 8
9 18. Odéen M, Westerlund H, Theorell T, Leineweber C, Eriksen H, Ursin H.
10 Expectancies, Socioeconomic Status, and Self-Rated Health: Use of the Simplified
11 TOMCATS Questionnaire. *Int J Behav Med* 2012: 1-10.
- 12 19. Ree E, Odeen M, Eriksen H, Indahl A, Ihlebæk C, Hetland J et al. Subjective Health
13 Complaints and Self-Rated Health: Are Expectancies More Important Than
14 Socioeconomic Status and Workload? *Int J Behav Med* 2014;21: 411-20.
- 15 20. Diggle PJH, P.J. Liang, K. Zeger, S.L. *Analysis of longitudinal data*. United
16 Kingdom: Oxford University Press, 2002.
- 17 21. Peters T, Richards S, Bankhead C, Ades A, Sterne J. Comparison of methods for
18 analysing cluster randomized trials: an example involving a factorial design. *Int J*
19 *Epidemiol* 2003;32 5: 840-6.
- 20 22. Sanson-Fisher RW, Bonevski B, Green LW, D'Este C. Limitations of the
21 Randomized Controlled Trial in Evaluating Population-Based Health Interventions.
22 *Am J Prev Med* 2007;33 2: 155-61.
- 23 23. Staal JB, Hlobil H, Koke AJ, Twisk JW, Smid T, van Mechelen W. Graded activity
24 for workers with low back pain: who benefits most and how does it work? *Arthritis*
25 *Rheum* 2008;59 5: 642-9.
- 26 24. Ree E, Harris A, Indahl A, Tveito TH, Malterud K. How can a brief intervention
27 contribute to coping with back pain? A focus group study about participants'
28 experiences. *Scand J Public Health* 2014;42 8: 821-6.
- 29 25. Sveinsdottir V, Eriksen HR, Reme SE. Assessing the role of cognitive behavioral
30 therapy in the management of chronic nonspecific back pain. *J Pain Res* 2012;5: 371-
31 80.
- 32 26. George SZ, Fritz JM, Bialosky JE, Donald DA. The Effect of a Fear-Avoidance-
33 Based Physical Therapy Intervention for Patients With Acute Low Back Pain: Results
34 of a Randomized Clinical Trial. *Spine* 2003;28 23: 2551-60.
- 35 27. Statistics Norway. Indicators for gender equality in municipalities, 2013,
36 <https://www.ssb.no/en/befolkning/statistikker/likekom/aar/2015-03-02> (2015,
37 accessed 10 December 2015)
- 38 28. Statistics Norway. Sickness absence for employees, by sex, industry (SIC2007) and
39 institutional sector (per cent),
40 [https://www.ssb.no/statistikkbanken/SelectVarVal/Define.asp?MainTable=SykefravS](https://www.ssb.no/statistikkbanken/SelectVarVal/Define.asp?MainTable=SykefravSektor&KortNavnWeb=sykefratot&PLanguage=1&checked=true)
41 [ektor&KortNavnWeb=sykefratot&PLanguage=1&checked=true](https://www.ssb.no/statistikkbanken/SelectVarVal/Define.asp?MainTable=SykefravSektor&KortNavnWeb=sykefratot&PLanguage=1&checked=true) (2014, accessed 10
42 December 2015).
- 43 29. Hagen EM, Svensen E, Eriksen HR, Ihlebæk CM, Ursin H. Comorbid Subjective
44 Health Complaints in Low Back Pain. *Spine* 2006;31 13: 1491-95.
- 45 30. Maeland S, Werner EL, Rosendal M, Jornsottir IH, Magnussen LH, Ursin H, Eriksen
46 HR. Diagnoses of patients with severe subjective health complaints in Scandinavia: A
47 cross sectional study. *ISRN Public Health* 2012;1-9.
- 48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow chart of participants: EPS = Education and Peer Support. EPSOC = Education, Peer Support and Outpatient Clinic.

Table 1: Number, percentages, means and standard deviations (SD) in the intervention and control group for the predictor variables: Low back pain, Deyo's myths (myth lifting, myth X-ray), pain-related fear, and helplessness/hopelessness. Differences between groups at baseline tested with independent-samples *t*-tests.

	Intervention	Control	Intervention	Control	<i>t</i> -value	<i>p</i> -value
	<i>n</i> (%)	<i>n</i> (%)	Mean (SD)	Mean (SD)		
Low back pain (0-3)^a	635	206	0.96 (0.9)	1.10 (40.9)	-1.76	.079
Low	434 (68.3)	128 (62.1)				
High	201 (31.7)	78 (37.9)				
Myth lifting (1-5)^b	620	206	3.26 (0.9)	3.22 (1.1)	0.46	.645
Low	408 (65.8)	125 (60.7)				
High	212 (34.2)	81 (39.3)				
Myth X-ray (1-5)^b	614	203	3.05 (1.1)	3.04 (1.2)	0.03	.976
Low	134 (66.4)	134 (66.0)				
High	206 (33.6)	69 (34.0)				
Pain-related fear (13-46)^c	623	207	25.36 (6.2)	25.47 (5.8)	-0.23	.816
Low	331 (53.1)	108 (52.2)				
High	292 (46.9)	99 (47.8)				
Helplessness/hopelessness (6-30)^d	628	205	10.32 (3.6)	10.01 (3.5)	1.06	.289
Low	363 (57.8)	127 (62.0)				
High	265 (42.2)	78 (38.0)				

^aLow scores = no or some complaints; high scores = much or severe complaints

^bLow scores = totally disagree, disagree, neither disagree nor agree; high scores = agree and totally agree

^cLow scores = on and below the mean (≤ 25.4); high scores = above the mean (> 25.4)

^dLow scores = on and below the mean (≤ 10.2); high scores = above the mean (> 10.2)

Table 2. Mean and standard deviation (SD) of sick leave days in blocks of three months the year before and after the intervention, and percent of participants on sick leave for one or more days during the three months periods.

	Months 12-9	Months 9-6	Months 6-3	Months 3-0	Months 0-3	Months 3-6	Months 6-9	Months 9-12
Intervention (n = 646)								
Mean (SD)	9.26 (23.1)	8.66 (22.6)	8.96 (23.7)	7.18 (21.1)	6.51 (18.3)	9.26 (23.7)	10.50 (24.8)	9.63 (23.3)
% on sick leave	19.2	18.4	16.6	15.9	16.9	17.0	21.2	20.3
Control (n = 211)								
Mean (SD)	6.48 (19.9)	6.52 (18.9)	4.39 (15.5)	8.01 (22.6)	9.28 (23.8)	11.45 (27.3)	8.51 (23.1)	7.37 (20.5)
% on sick leave	14.2	14.2	10.9	15.2	18.5	19.9	17.5	19.0
Total (n = 857)								
Mean (SD)	8.58 (22.4)	8.13 (21.8)	7.84 (22.1)	7.38 (21.5)	7.19 (19.8)	9.80 (24.6)	10.01 (24.4)	9.08 (22.7)
% on sick leave	18.0	17.4	15.2	15.8	17.3	17.7	20.3	20.0

Table 3: Unadjusted mean scores and 95% CI for sick leave days stratified by high and low baseline scores on low back pain, Deyo's myths (myth lifting, myth X-ray), pain-related fear, and helplessness/hopelessness in the intervention and control group.

		Intervention	Control
		Mean (95% CI)	Mean (95% CI)
Low back pain_low^a	0-3	5.93 (4.33 - 7.54)	8.02 (4.03 - 12.02)
	3-6	7.50 (5.48 - 9.51)	9.63 (5.17 - 14.10)
	6-9	7.52 (5.55 - 9.50)	8.34 (4.44 - 12.24)
	9-12	6.29 (4.56 - 8.01)	5.30 (2.35 - 8.25)
Low back pain_high	0-3	8.08 (5.16 - 10.98)	10.22 (5.06 - 15.37)
	3-6	13.48 (9.60 - 17.36)	13.99 (7.51 - 20.46)
	6-9	17.33 (13.07 - 21.60)	9.33 (3.91 - 14.75)
	9-12	16.70 (12.53 - 20.87)	11.04 (5.48 - 16.60)
Myth lifting_low^b	0-3	6.50 (4.70-8.29)	10.33 (5.92 - 14.74)
	3-6	9.74 (7.44 - 12.03)	11.93 (6.90 - 14.74)
	6-9	10.12 (7.78 - 12.45)	9.27 (5.07 - 13.47)
	9-12	9.49 (7.26 - 11.72)	6.12 (3.03 - 9.21)
Myth lifting_high	0-3	7.12 (4.60 - 9.65)	7.14 (2.80 - 11.46)
	3-6	9.48 (6.12 - 12.85)	9.77 (4.42 - 15.11)
	6-9	12.34 (8.67 - 16.00)	7.86 (3.05 - 12.68)
	9-12	10.70 (7.34 - 14.07)	9.77 (4.45 - 15.07)
Myth X-ray_low^b	0-3	5.98 (4.28 - 7.68)	8.92 (4.98 - 12.87)
	3-6	8.22 (6.07 - 10.37)	10.22 (5.77 - 14.68)
	6-9	8.80 (6.59 - 11.02)	6.87 (3.41 - 10.32)
	9-12	7.60 (5.56 - 9.63)	6.40 (3.25 - 9.56)
Myth X-ray_high	0-3	8.24 (5.41 - 11.06)	8.45 (3.34 - 13.55)
	3-6	12.18 (8.48 - 15.88)	10.94 (4.73 - 17.16)
	6-9	15.13 (11.15 - 19.13)	10.83 (4.61 - 17.04)
	9-12	14.51 (10.68 - 18.34)	9.93 (4.21 - 15.64)
Pain-related fear_low^c	0-3	5.03 (3.39 - 6.66)	10.52 (5.68 - 15.35)
	3-6	9.62 (7.05 - 12.19)	11.84 (6.55 - 17.13)
	6-9	10.17 (7.61 - 12.74)	8.71 (4.21 - 13.22)
	9-12	8.76 (6.36 - 11.17)	7.06 (3.17 - 10.94)
Pain-related fear_high	0-3	8.14 (5.68 - 10.59)	7.40 (3.43 - 11.38)
	3-6	9.27 (6.54 - 12.01)	10.60 (5.43 - 15.76)
	6-9	11.23 (8.22 - 14.23)	8.32 (3.92 - 12.73)
	9-12	10.89 (8.06 - 13.72)	8.02 (3.96 - 12.08)
Helplessness/hopelessness_low^d	0-3	4.36 (2.88 - 5.84)	6.70 (3.22 - 10.18)
	3-6	7.92 (5.68 - 10.16)	9.67 (5.40 - 13.94)
	6-9	9.07 (6.66 - 11.48)	6.24 (2.59 - 9.88)
	9-12	8.09 (5.90 - 10.29)	5.24 (2.26 - 8.23)
Helplessness/hopelessness_high	0-3	9.56 (6.84 - 12.28)	13.63 (7.29 - 19.97)
	3-6	11.07 (7.93 - 14.21)	14.90 (7.90 - 21.89)
	6-9	12.63 (9.43 - 15.84)	12.42 (6.62 - 18.23)
	9-12	11.52 (8.45 - 14.59)	10.86 (5.38 - 16.34)

^aLow scores = no or some complaints; high scores = much or severe complaints

^bLow scores = totally disagree, disagree, neither disagree nor agree; high scores = agree and totally agree

^cLow scores = on and below the mean (≤ 25.4); high scores = above the mean (> 25.4)

^dLow scores = on and below the mean (≤ 10.2); high scores = above the mean (> 10.2)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Table 4: Adjusted mean difference with 95% CI for the intervention and control group in effect on days of sick leave, and for the interaction effect of days of sick leave for the two levels (high/low) of low back pain, Deyo's myths (myth lifting, myth X-ray), pain-related fear, and helplessness/hopelessness, with intervention. Differences between groups were tested with generalized estimating equations (GEE) adjusted for days of sick leave the year preceding the intervention and workplace department (unit).

	Months	Mean diff (95% CI)	p-value
Intervention vs Control	0-3	-4.94 (-7.79 - -2.08)	.001
	3-6	-4.36 (-7.90 - -0.82)	.016
	6-9	-0.18 (-3.69 - 3.33)	.922
	9-12	-0.94 (-3.61 - 3.80)	.961
Low back pain (low vs high)^a	0-3	-1.24 (-8.16 - 5.68)	.725
	3-6	0.43 (-7.56 - 8.43)	.915
	6-9	7.63 (-0.30 - 15.55)	.059
	9-12	3.48 (-4.86 - 11.83)	.413
Myth lifting (low vs high)^b	0-3	4.47 (-2.37 - 11.32)	.200
	3-6	2.56 (-7.36 - 12.48)	.612
	6-9	4.28 (-4.47 - 13.04)	.338
	9-12	-1.78 (-9.21 - 5.65)	.639
Myth X-ray (low vs high)^b	0-3	1.58 (-6.55 - 9.72)	.703
	3-6	2.09 (-7.84 - 12.02)	.679
	6-9	1.22 (-8.27 - 10.72)	.801
	9-12	2.24 (-6.23 - 11.10)	.621
Pain-related fear (low vs high)^c	0-3	7.58 (0.24 - 14.91)	.043
	3-6	2.25 (-9.05 - 13.55)	.696
	6-9	2.79 (-6.39 - 11.97)	.551
	9-12	2.51 (-4.53 - 9.56)	.485
Helplessness/hopelessness (low vs high)^d	0-3	-3.05 (-10.45 - 4.35)	.419
	3-6	-3.40 (-12.96 - 6.15)	.485
	6-9	-3.95 (-12.20 - 4.30)	.348
	9-12	-3.51 (-10.10 - 3.09)	.297

^aLow scores = no or some complaints and high scores = much or severe complaints

^bLow scores = totally disagree, disagree, neither disagree nor agree and high scores = agree and totally agree

^cLow scores = on and below the mean (≤ 25.4) and high scores = above the mean (> 25.4)

^dLow scores = on and below the mean (≤ 10.2) and high scores = above the mean (> 10.2)

Table 1: CONSORT 2010 checklist of information to include when reporting a cluster randomised trial

Section/Topic	Item No	Standard Checklist item	Extension for cluster designs	Page No *
Title and abstract				
	1a	Identification as a randomised trial in the title	Identification as a cluster randomised trial in the title	2
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) ^{1,2}	See table 2	2
Introduction				
Background and objectives	2a	Scientific background and explanation of rationale	Rationale for using a cluster design	4
	2b	Specific objectives or hypotheses	Whether objectives pertain to the cluster level, the individual participant level or both	4
Methods				
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	Definition of cluster and description of how the design features apply to the clusters	4, 5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons		
Participants	4a	Eligibility criteria for participants	Eligibility criteria for clusters	4
	4b	Settings and locations where the data were collected		
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Whether interventions pertain to the cluster level, the individual participant level or both	5
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and	Whether outcome measures pertain to the cluster level, the individual participant level or both	6

		when they were assessed		
	6b	Any changes to trial outcomes after the trial commenced, with reasons		
Sample size	7a	How sample size was determined	Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or <i>k</i>), and an indication of its uncertainty	
	7b	When applicable, explanation of any interim analyses and stopping guidelines		
Randomisation:				
Sequence generation	8a	Method used to generate the random allocation sequence		5
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	Details of stratification or matching if used	5
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level or both	5
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Replace by 10a, 10b and 10c	
	10a		Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions	5
	10b		Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete	4, 5

			enumeration, random sampling)	
	10c		From whom consent was sought (representatives of the cluster, or individual cluster members, or both), and whether consent was sought before or after randomisation	5
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how		
	11b	If relevant, description of the similarity of interventions		
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	How clustering was taken into account	8
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses		8
Results				
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	For each group, the numbers of clusters that were randomly assigned, received intended treatment, and were analysed for the primary outcome	Reported in flow diagram
	13b	For each group, losses and exclusions after randomisation, together with reasons	For each group, losses and exclusions for both clusters and individual cluster members	Reported in flow diagram
Recruitment	14a	Dates defining the periods of recruitment and follow-up		4
	14b	Why the trial ended or was stopped		
Baseline data	15	A table showing baseline demographic and clinical	Baseline characteristics for the individual and cluster levels as	Table 1 and 2

		characteristics for each group	applicable for each group	
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	For each group, number of clusters included in each analysis	Reported in flow diagram
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for each primary outcome	
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended		
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory		9,10
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms ³)		
Discussion				
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		12
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Generalisability to clusters and/or individual participants (as relevant)	12
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		10-13
Other information				
Registration	23	Registration number and		2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	13

* Note: page numbers optional depending on journal requirements

For Peer Review Only

Table 2: Extension of CONSORT for abstracts^{1,2} to reports of cluster randomised trials

Item	Standard Checklist item	Extension for cluster trials
Title	Identification of study as randomised	Identification of study as cluster randomised
Trial design	Description of the trial design (e.g. parallel, cluster, non-inferiority)	
Methods		
Participants	Eligibility criteria for participants and the settings where the data were collected	Eligibility criteria for clusters
Interventions	Interventions intended for each group	
Objective	Specific objective or hypothesis	Whether objective or hypothesis pertains to the cluster level, the individual participant level or both
Outcome	Clearly defined primary outcome for this report	Whether the primary outcome pertains to the cluster level, the individual participant level or both
Randomization	How participants were allocated to interventions	How clusters were allocated to interventions
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	
Results		
Numbers randomized	Number of participants randomized to each group	Number of clusters randomized to each group
Recruitment	Trial status ¹	
Numbers analysed	Number of participants analysed in each group	Number of clusters analysed in each group
Outcome	For the primary outcome, a result for each group and the estimated effect size and its precision	Results at the cluster or individual participant level as applicable for each primary outcome
Harms	Important adverse events or side effects	
Conclusions	General interpretation of the results	
Trial registration	Registration number and name of trial register	
Funding	Source of funding	

¹ Relevant to Conference Abstracts

REFERENCES

- 1 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet* 2008, 371:281-283
- 2 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG at al (2008) CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med* 5(1): e20
- 3 Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004; 141(10):781-788.